期刊
BIOCONJUGATE CHEMISTRY
卷 29, 期 4, 页码 852-860出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.bioconjchem.7b00758
关键词
-
类别
资金
- National Basic Research Programs of China (973 Program) [2016YFA0201200]
- National Natural Science Foundation of China [51525203]
- Joint International Research Laboratory of Carbon-Based Functional Materials and Devices
- Collaborative Innovation Center of Suzhou Nano Science and Technology
- Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions
Red blood cells (RBCs), also called erythrocytes, are the most abundant type of blood cells. Recently, RBCs have been extensively studied as drug delivery systems because of their remarkable properties, including their inherent biocompatibility, low immunogenicity, flexibility, and long systemic circulation. Over the years, a number of different RBC-based drug delivery systems, including genetically engineered RBCs, nongenetically engineered RBCs, and RBC membrane-coated nanopartides, have been explored, aiming at diverse biomedical applications. These techniques may address many challenging issues faced by traditional drug delivery systems, as demonstrated by the many successful preclinical results. Novel techniques dedicated to producing drug-carrying RBCs are currently undergoing the transition from preclinical research to the clinical realm. In this Topical Review, we will summarize the latest progress in the development of RBC-based smart delivery systems for various biomedical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据